Literature DB >> 11249804

Onset of action of antipsychotics in the treatment of mania.

M Tohen1, T G Jacobs, P D Feldman.   

Abstract

INTRODUCTION: An important consideration in treating acute mania is the promptness with which a chosen therapy can bring symptom amelioration. This article reviews the available published data from controlled, blinded studies regarding the latency of responses to antipsychotics in patients with acute mania.
METHODS: Articles for this review were obtained from a search of the Medline database (1966- 1999), using the following keywords and phrases: antipsychotic, atypical, bipolar disorder, mania, neuroleptic, typical. The bibliographic sections of articles gleaned from this search were used to direct further inquiries.
RESULTS: Although information regarding the onset of action of antipsychotics is limited, we discovered data for four typical and three atypical antipsychotics. Drugs with the fastest onsets include haloperidol, risperidone, and olanzapine, with onsets appearing in 2 6 days. Chlorpromazine and thiothixene were at the slowest end of the continuum, with onsets of 2 weeks or longer. Data regarding pimozide are mixed, with some studies showing an onset equivalent to that of the 'fast' compounds and others showing one similar to that of the 'slow' compounds.
CONCLUSIONS: Choice of therapy should consider not only efficacy and safety, but also onset speed. Atypical antipsychotics appear to offer safer, faster, and more effective therapies.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11249804     DOI: 10.1034/j.1399-5618.2000.20307.x

Source DB:  PubMed          Journal:  Bipolar Disord        ISSN: 1398-5647            Impact factor:   6.744


  12 in total

1.  Outcome and length of stay in psychiatric hospitalization, the experience of the University Clinic of Turin.

Authors:  Paola Rocca; C Mingrone; T Mongini; C Montemagni; L Pulvirenti; G Rocca; F Bogetto
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2009-07-08       Impact factor: 4.328

Review 2.  Treatment of Bipolar Disorder in a Lifetime Perspective: Is Lithium Still the Best Choice?

Authors:  Gabriele Sani; Giulio Perugi; Leonardo Tondo
Journal:  Clin Drug Investig       Date:  2017-08       Impact factor: 2.859

Review 3.  Pharmacologic treatment of geriatric mania.

Authors:  William M McDonald; John Wermager
Journal:  Curr Psychiatry Rep       Date:  2002-02       Impact factor: 5.285

Review 4.  Treating bipolar disorder. Evidence-based guidelines for family medicine.

Authors:  Roger S McIntyre; Deborah A Mancini; Peter Lin; John Jordan
Journal:  Can Fam Physician       Date:  2004-03       Impact factor: 3.275

5.  Comparing tolerability of olanzapine in schizophrenia and affective disorders: a meta-analysis.

Authors:  Hoda Moteshafi; Simon Zhornitsky; Sarah Brunelle; Emmanuel Stip
Journal:  Drug Saf       Date:  2012-10-01       Impact factor: 5.606

6.  Clinical outcome and length of stay in an Italian Psychiatric Emergency Service.

Authors:  T Frieri; C Montemagni; G Rocca; P Rocca; V Villari
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2012-10-30       Impact factor: 4.328

7.  The extracellular signal-regulated kinase pathway contributes to the control of behavioral excitement.

Authors:  S R Engel; T K Creson; Y Hao; Y Shen; S Maeng; T Nekrasova; G E Landreth; H K Manji; G Chen
Journal:  Mol Psychiatry       Date:  2008-01-29       Impact factor: 15.992

Review 8.  Aripiprazole in the maintenance treatment of bipolar disorder: a critical review of the evidence and its dissemination into the scientific literature.

Authors:  Alexander C Tsai; Nicholas Z Rosenlicht; Jon N Jureidini; Peter I Parry; Glen I Spielmans; David Healy
Journal:  PLoS Med       Date:  2011-05-03       Impact factor: 11.069

9.  Methylphenidate in mania project (MEMAP): study protocol of an international randomised double-blind placebo-controlled study on the initial treatment of acute mania with methylphenidate.

Authors:  Michael Kluge; Ulrich Hegerl; Christian Sander; Jens Dietzel; Roland Mergl; Istvan Bitter; Koen Demyttenaere; Ricardo Gusmão; Ana Gonzalez-Pinto; Victor Perez-Sola; Eduard Vieta; Georg Juckel; Ulrich S Zimmermann; Michael Bauer; Pascal Sienaert; Sónia Quintão; Marc-Andreas Edel; Csilla Bolyos; Jose Luis Ayuso-Mateos; Pilar López-García
Journal:  BMC Psychiatry       Date:  2013-02-27       Impact factor: 3.630

10.  Altered neuronal markers following treatment with mood stabilizer and antipsychotic drugs indicate an increased likelihood of neurotransmitter release.

Authors:  Elizabeth Scarr; Brian Dean
Journal:  Clin Psychopharmacol Neurosci       Date:  2012-04-30       Impact factor: 2.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.